Latest news with #BNTX
Globe and Mail
7 days ago
- Business
- Globe and Mail
Bristol Myers Collaborates With BNTX for Oncology Candidate
BMY announced a strategic collaboration agreement with BioNTech BNTX. Both companies have entered into an agreement for the global co-development and co-commercialization of BioNTech's investigational bispecific antibody BNT327 across numerous solid tumor types. BNT327 is a novel investigational bispecific antibody combining two complementary, validated mechanisms in oncology into a single molecule. Shares of BNTX surged on the deal announcement. Shares of Bristol Myers lost 12.8% year to date compared with the industry 's decline of 2.2%. More on BMY & BNTX Agreement Per the terms, BMY and BNTX will jointly develop and commercialize BNT327, including the development of BNT327 as monotherapy and in combination with other products. Both BMY and BNTX own the right to develop BNT327 independently in further indications and combinations, including combinations of BNT327 with proprietary pipeline assets. Per the terms, BMY will make an upfront payment of $1.5 billion to BioNTech. In addition, BNTX will also receive $2 billion in non-contingent anniversary payments through 2028. BioNTech is also eligible to receive up to $7.6 billion in additional development, regulatory and commercial milestones. Both the companies will jointly share development and manufacturing costs along with profits on an equal basis. BNT327, a next-generation bispecific antibody candidate, targets PD-L1 and VEGF-A. It is currently being evaluated in multiple ongoing trials with more than 1,000 patients treated to date, including phase III studies with registrational potential evaluating BNT327 as first-line treatment in extensive stage small cell lung cancer (ES-SCLC) and non-small cell lung cancer (NSCLC). A phase III study evaluating the candidate in triple negative breast cancer (TNBC) is planned to start by the end of 2025. Data from ongoing trials (on a preliminary basis) underscore the potential for combining anti-PD-L1 and anti-VEGF-A – two well-established therapeutic targets – into a single molecule to deliver synergistic clinical benefits for patients across multiple tumor types. BMY Looks to Diversify Business BMY is depending on newer drugs like Opdualag, Reblozyl and Breyanzi to stabilize its revenue base as its legacy drugs face generic competition. BMY earlier won FDA approval for xanomeline and trospium chloride (formerly KarXT), an oral medication for the treatment of schizophrenia, in adults, under the brand name Cobenfy. The approval broadens BMY's portfolio. Cobenfy represents the first new pharmacological approach to treating schizophrenia in decades. This drug is expected to contribute meaningfully to BMY's top line in the coming years. BMY has experienced a few pipeline setbacks in recent months, which negatively impacted its share price. The late-stage ODYSSEY-HCM study evaluating cardiovascular drug Camzyos for the treatment of adult patients with symptomatic New York Heart Association (NYHA) class II-III non-obstructive hypertrophic cardiomyopathy did not meet its dual primary endpoints. The top-line results from the phase III ARISE study on schizophrenia drug Cobenfy were also disappointing. The study is evaluating the efficacy and safety of the drug as an adjunctive treatment to atypical antipsychotics in adults with inadequately controlled symptoms of schizophrenia. Developing bispecific antibodies that target two proteins, namely PD-1 and VEGF, has lately been one of the lucrative areas in cancer treatment. In November, Merck signed a deal with China-based LaNova Medicines for the latter's PD-1xVEGF targeting bispecific antibody candidate, LM-299. The latest entrant into this space is Pfizer PFE, which recently entered a multi-billion-dollar deal with Chinese biotech 3SBio for the latter's PD-1/VEGF bispecific antibody SSGJ-707. The deal is expected to be complete in third-quarter 2025. BMY's Zacks Rank & Stocks to Consider Bristol Myers currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the pharma/biotech sector are Novartis NVS and Pfizer, both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. The Zacks Consensus Estimate for Novartis' 2025 earnings per share (EPS) has risen from $8.47 to $8.74 over the past 60 days. EPS estimates for 2026 have jumped 20 cents to $9.02 during this timeframe. The stock has risen 18.6% so far this year. Pfizer's 2025 EPS estimate has risen from $2.97 to $3.06 in the past 60 days, while that for 2026 has gone up from $2.99 to $3.09 over the same timeframe. Zacks' Research Chief Names "Stock Most Likely to Double" Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest. This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Bristol Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report BioNTech SE Sponsored ADR (BNTX): Free Stock Analysis Report
Yahoo
02-06-2025
- Business
- Yahoo
BioNTech Gains 20% On $11.1 Billion Bristol Deal
BioNTech (NASDAQ:BNTX) surged 20% after Bristol Myers Squibb (NYSE:BMY) agreed to license its bispecific antibody BNT327targeting PD-L1 and VEGF-Afor solid tumors in a deal worth up to $11.1 billion. Under the agreement, BMY will pay a $1.5 billion upfront fee and $2 billion in guaranteed payments through 2028, with BioNTech eligible for up to $7.6 billion in milestones. Both companies will fund development and manufacturing costs equally and split global profits or losses. BNT327 is currently in a Phase 3 trial as a first-line treatment for extensive-stage small-cell and non-small-cell lung cancers, and a Phase 3 study in triple-negative breast cancer will launch by year-end. BMY and BNTX retain rights to pursue additional indications and combination regimens. Warning! GuruFocus has detected 2 Warning Signs with BNTX. Street analysts applauded the collaboration. BMO Capital Markets' Evan David Seigerman noted that Bristol gains a next-generation molecule to potentially replace Opdivo, while BioNTech taps Bristol's global distribution and oncology development expertise. Raymond James' Sean McCutcheon added that the move shores up Bristol's mid- to long-term growth pipeline ahead of an anticipated Opdivo revenue gap post-2028. Investors should care because this partnership accelerates BNT327's path to market with a Tier 1 oncology partner, de-risks late-stage development, and provides BioNTech with substantial non-dilutive capitalwhile Bristol secures a promising immunotherapy to bolster its portfolio. With the first $1.5 billion payment already recognized, markets will focus on upcoming BNT327 Phase 3 readouts and any future milestone announcements that unlock the remaining $7.6 billion. This article first appeared on GuruFocus.
Yahoo
02-06-2025
- Business
- Yahoo
M&A is 'lifeblood' of biopharma: Analyst on Sanofi-Blueprint deal
The American Society of Clinical Oncology (ASCO) is kicking off its annual meeting in Chicago this week, with all eyes on the latest developments and acquisition deals in the pharmaceutical space. Sanofi (SNY, is set to buy Blueprint Medicines (BPMC) for over $9 billion, while Bristol-Myers Squibb (BMY) plans to license a cancer drug from BioNTech (BNTX). BMO Capital Markets managing director of biopharma equity research Evan Seigerman comments on the M&A activity and regulatory oversight in the biopharma space. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.
Yahoo
21-05-2025
- Business
- Yahoo
BioNTech Strengthens UK Ties with Investment of Up to $1.33 Billion
German vaccine maker BioNTech SE (NASDAQ:BNTX) revealed on May 20 that it intends to boost its presence in the UK with an investment of up to £1 billion ($1.33 billion) over the next decade, focusing on expanding its research and development operations. According to BioNTech SE (NASDAQ:BNTX), its UK subsidiary has signed a grant agreement with the British government, furthering a partnership that began in January 2023. As part of this expanded collaboration, BioNTech has committed to enrolling as many as 10,000 patients in clinical trials for personalized cancer treatments by the end of 2030, along with making significant investments to grow its operations in the UK. The agreement was formally signed with UK Science Secretary Peter Kyle. Under the terms, the UK government will provide up to £129 million in grant funding over the next ten years. BioNTech SE (NASDAQ:BNTX) plans to use the funding to establish two new R&D facilities, including one in Cambridge. These initiatives are aligned with the company's broader goal of delivering several cancer therapies to market by 2030. In a statement, the UK government regarded this as "one of the biggest investments in the history of UK life sciences" and highlighted that the investment is expected to generate hundreds of high-skilled jobs and lead to the creation of new research hubs aimed at driving medical innovation. BNTX is up by over 7% in the past 12 months. While we acknowledge the potential of BNTX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BNTX and that has 100x upside potential, check out our report about this cheapest AI stock. READ MORE: and Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
06-05-2025
- Business
- Yahoo
BioNTech (NasdaqGS:BNTX) Appoints New CFO As Q1 Sales Fall To €183 Million
BioNTech recently appointed Ramón Zapata-Gomez as its new CFO, a move reflecting the company's focus on realigning its financial strategy, particularly in oncology. Despite confirming its earnings guidance for 2025, the company's Q1 performance showed a continued net loss, highlighting financial challenges. Over the past month, the company's share price moved 15%, amidst a market environment where indices like the Dow Jones and Nasdaq showed mixed responses to broader economic factors, such as tariff negotiations and central bank policies. BioNTech's developments likely added weight to the broader market trends rather than diverging significantly. Buy, Hold or Sell BioNTech? View our complete analysis and fair value estimate and you decide. NasdaqGS:BNTX Revenue & Expenses Breakdown as at May 2025 AI is about to change healthcare. These 26 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early. The appointment of Ramón Zapata-Gomez as CFO underscores BioNTech's commitment to refining its financial strategy, with a clear focus on oncology. This strategic realignment could influence the company's narrative by potentially boosting confidence in its ability to enhance operational efficiency and drive revenue growth, particularly through its promising mRNA cancer immunotherapy initiatives. As the company seeks to balance increased R&D expenditures with declining COVID-19 vaccine demand, the new leadership might be key in managing these financial complexities. Over a longer five-year span, BioNTech's total shareholder return, including dividends, surged by 104.24%. This performance provides context to the recent share price increase, which reflects a broader trend rather than a short-term anomaly. Comparatively, over the past year, BioNTech performed in line with the overall US market, which yielded a 9.3% return, and exceeded the US Biotechs industry, which experienced a decline of 6.9%. This suggests that while BioNTech has struggled with profitability, it remains an attractive investment relative to its sector peers. In terms of revenue and earnings forecasts, the recent strategic moves, including the acquisition of Biotheus to strengthen its position in China, could impact future growth projections. Despite this, analysts maintain subdued expectations with forecasts indicating ongoing unprofitability over the next three years. The stock currently trades at US$104.00, positioning it below the consensus analyst price target of US$138.37 by 36.9%. This discount suggests potential upside should BioNTech's strategic initiatives successfully materialize into revenue-generating opportunities. However, evaluating these forecasts against personal research and market context remains crucial for investors.
